JP2005506982A - キナーゼ阻害剤としての３−（４，５，６，７−テトラヒドロインドール−２−イルメチリデン）−２−インドリノン誘導体 - Google Patents

キナーゼ阻害剤としての３−（４，５，６，７−テトラヒドロインドール−２−イルメチリデン）−２−インドリノン誘導体 Download PDF

Info

Publication number
JP2005506982A
JP2005506982A JP2003526891A JP2003526891A JP2005506982A JP 2005506982 A JP2005506982 A JP 2005506982A JP 2003526891 A JP2003526891 A JP 2003526891A JP 2003526891 A JP2003526891 A JP 2003526891A JP 2005506982 A JP2005506982 A JP 2005506982A
Authority
JP
Japan
Prior art keywords
compound
alkyl
piperazin
hydrogen
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003526891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506982A5 (OSRAM
Inventor
リャン，コンシン
グアン，フイピン
タン，ペン，チョー
ブレーク，ロバート，エー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of JP2005506982A publication Critical patent/JP2005506982A/ja
Publication of JP2005506982A5 publication Critical patent/JP2005506982A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2003526891A 2001-09-10 2002-09-10 キナーゼ阻害剤としての３−（４，５，６，７−テトラヒドロインドール−２−イルメチリデン）−２−インドリノン誘導体 Withdrawn JP2005506982A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31850801P 2001-09-10 2001-09-10
PCT/US2002/025974 WO2003022815A1 (en) 2001-09-10 2002-09-10 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2005506982A true JP2005506982A (ja) 2005-03-10
JP2005506982A5 JP2005506982A5 (OSRAM) 2006-01-05

Family

ID=23238468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526891A Withdrawn JP2005506982A (ja) 2001-09-10 2002-09-10 キナーゼ阻害剤としての３−（４，５，６，７−テトラヒドロインドール−２−イルメチリデン）−２−インドリノン誘導体

Country Status (7)

Country Link
US (2) US6777417B2 (OSRAM)
EP (1) EP1436259A1 (OSRAM)
JP (1) JP2005506982A (OSRAM)
BR (1) BR0212435A (OSRAM)
CA (1) CA2459879A1 (OSRAM)
MX (1) MXPA04002242A (OSRAM)
WO (1) WO2003022815A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526838A (ja) * 2007-05-14 2010-08-05 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ窒素複素環誘導体、その調製および薬学的使用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101230L (sv) * 2001-04-06 2002-10-07 Innoventus Project Ab Ny användning av en tyrosinkinasinhibitor
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2004284084A1 (en) 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2485106C2 (ru) * 2005-06-08 2013-06-20 Райджел Фамэсьютикэлз, Инк. Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
HRP20170317T1 (hr) * 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) * 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US7897602B2 (en) * 2009-01-12 2011-03-01 Development Center For Biotechnology Indolinone compounds as kinase inhibitors
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20130197229A1 (en) * 2010-10-13 2013-08-01 Christopher Matthews Method of making azaindazole derivatives
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
WO2014012859A1 (en) 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
CA2383623A1 (en) * 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526838A (ja) * 2007-05-14 2010-08-05 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ窒素複素環誘導体、その調製および薬学的使用

Also Published As

Publication number Publication date
US6777417B2 (en) 2004-08-17
US20030119819A1 (en) 2003-06-26
WO2003022815A1 (en) 2003-03-20
BR0212435A (pt) 2004-08-17
MXPA04002242A (es) 2005-03-07
EP1436259A1 (en) 2004-07-14
CA2459879A1 (en) 2003-03-20
US20040266855A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
US6777417B2 (en) 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
JP3663382B2 (ja) ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
JP3677501B2 (ja) 蛋白質キナーゼ阻害剤としての３−（４−アミドピロール−２−イルメチリデン）−２−インドリノン誘導体
US8809534B2 (en) Compounds as tyrosine kinase modulators
CN101959404B (zh) 单磷酸腺苷活化蛋白激酶调节剂
US10214515B2 (en) Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
CN103582643B (zh) 蛋白激酶抑制剂
JP2004518669A (ja) ４−アリール置換インドリノン
US6642232B2 (en) 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
US8486936B2 (en) Antagonist of smoothened
EP1644377A1 (en) Triazolotriazine compounds and uses thereof
JP2003513091A (ja) 複素環で置換されたピラゾロン
US20050014755A1 (en) Tetracyclic compounds as c-Met inhibitors
US7053114B2 (en) Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
KR20240021239A (ko) Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
CN111542522A (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
JP4564713B2 (ja) 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
CN109153686B (zh) 一类蛋白激酶抑制剂
US20070244110A1 (en) Treatment of prostate cancer, melanoma or hepatic cancer
CN120302969A (zh) 可用作iap抑制剂的化合物和组合物
US11254654B2 (en) Heterochromatin gene repression inhibitors
JP2018522899A (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
WO2005113561A1 (en) Cyclicsulfonate pyrrole indolinones as kinase inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050921

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060602